• Like
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
3,233
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
43
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Get more info on this report!Vaccines 2011: World Market Analysis, Key Players, and CriticalTrends in a Fast-Changing IndustryKalorama InformationThe high growth rates and successful launch of several products recently have keptinterest in the global vaccine market high. The global market for vaccines experiencedstrong growth through 2010 and this is expected to continue through the forecastperiod. Growth is being fueled by new product introductions and rising usage in allregions.Kalorama Information has been closely following vaccine markets and since 2003 hasinstituted a yearly market research report schedule to keep up with fast-movingdevelopments. Our latest comprehensive update, Vaccines 2011: World MarketAnalysis, Key Players, and Critical Trends in a Fast-Changing Industry, examines themarket for vaccines used in humans for various disease. This state-of-the-industryreport is a must-have for any executive who wants to stay on top of a rapidly changingmarket and see what’s expected based on analysis of major company pipelines.Trends are discussed in this report including the introduction of needle-free systemsand the production of vaccines, as well as product safety, supply shortages, and the useof vaccines to prevent pandemics and address bioterrorism, and innovations in vaccinedelivery systems. News and reports of vaccine-related illness tend to exacerbate thepublic’s fears and result in higher rates of non-immunization, and these are discussed inthis edition of the report.The report covers only commercialized vaccines and developmental vaccines fordiseases that are already vaccine-preventable; it does not cover emerging vaccines fordiseases that are not currently vaccine-preventable.Included in this report are current market size and forecast for the following vaccines:Pediatric Vaccines: Combinations Hepatitis HIB MMR Pneumococcal
  • 2. Poliovirus Varicella Other PediatricAdult Vaccines: Cervical Cancer Hepatitis Influenza Pneumococcal Travel; DT; Misc.Important trends such as vaccine safety, vaccine shortages, preventing pandemics,vaccines and bioterrorism, DNA vaccination, innovations in vaccine delivery systemsand innovations in vaccine Production are covered in the report.Kalorama has expanded the global perspective of this report in this edition, includingestimates of vaccine sales (pediatric and adult segments) in the following regions: U.S. Rest of North Amer. South America Europe Japan India China Rest of WorldIn addition, the report profiles key competitors in the vaccine industry. Companiesprofiled in the report include: AlphaVax, Inc. Bavarian Nordic A/S Baxter Healthcare Bharat Biotech Celldex Therapeutics Crucell / Johnson and Johnson Emergent biosolutions GlaxoSmithKline Medimmune Merck & Co. Inc Nabi Biopharmaceuticals Novartis Pfizer Sanofi Pasteur
  • 3. Revenue estimates for each market segment represent global revenues and areexpressed in current dollars. Estimates are provided for the historic 2005 to 2009 periodand forecasts are provided through 2014. Historical information for this report wasgathered from a wide variety of published sources including company reports andfilings, government documents, legal filings, trade journals, newspapers and businesspress, analysts’ reports and other sources. Interviews with company representativesand other experts were conducted to capture the perspectives from industryparticipants’ point of view and assess trends... these form the basis of the forecastingand competitive analysis.Additional Information Continued Climb for Pharma Vaccine RevenuesIn an industry facing patent expirations and layoffs, vaccine products continue to offergood news, according to healthcare market research publisher Kalorama Information.The world market for preventative vaccines totaled $25.3 billion in 2010, up from $22.1billion in 2009, according to its annual report on the industry, Vaccines 2011: WorldMarket Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. Thereport notes that the worldwide vaccine market is predicted to increase at a compoundannual rate of 9.3% during the next five years, as new product introductions continueand the products are sold to emerging markets."Vaccines are a priority at the major companies and there has been no let-up in thebusiness in the four years that we have been tracking it annually," said Bruce Carlson,publisher of Kalorama Information. "We continue to see over nine percent growth insales, and in some emerging markets the rate of growth is even faster. There is also astrong pipeline that should sustain growth as new products are launched."The healthcare market research firm indicated that sales to Latin America, India andChina will grow at double-digit rates.Vaccines are commonly segmented into two target markets, adult and pediatric.According to Kalorama Information, the pediatric vaccine market is larger, accountingfor more than half of the total market. Pediatric vaccines are also growing at a fasterrate than adult vaccines and this is expected to continue over the next five years.Pneumococcal and "combination" DTaP vaccines continue to drive growth in thepediatric sector, while influenza and hepatitis vaccine products are driving sales in theadult segment of the market.The world vaccines market is dominated by five major competitors: Sanofi Pasteur,GlaxoSmithKline, Merck & Co., Pfizer, and Novartis. Together, they held four-fifths ofthe market in 2010. All but Pfizer and Merck posted strong double-digit growth in theirvaccine businesses. Sanofi Pasteur, a subsidiary of Sanofi Aventis, was the leading
  • 4. manufacturer, according to Kalorama Information, with GlaxoSmithKline a close second.The companys position was largely due to its influenza products, although itspolio/pertussis/Hib products also account for a significant portion of its vaccine sales.More information is available from Kalorama Informations report, Vaccines 2011: WorldMarket Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, includingmarket forecasts, company profiles, and trends in the industry.More Drug Delivery Reports by Kalorama InformationNeedle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems forVaccine and Biologics by Kalorama InformationThe line between drug delivery and drug substance will continue to become moreelusive in the near future as shown in the analysis in this ...Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) byKalorama InformationDrug delivery is evolving at a rapid rate with new drug product formulations beingdiscovered frequently. Advanced drug delivery deals with developing solutions for new...The World Market for Diabetes Treatments by Kalorama InformationThis Kalorama Information report , The World Market for Diabetes Treatments, providesmarket estimates and forecasts for the world market for diabetes treatments. The ...The World Anesthesia Drug Market by Kalorama InformationThis Kalorama Information report - The World Anesthesia Drug Market - focuses onthree primary segments of anesthesia: General Anesthesia Local Anesthesia Adjunctive...Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems byKalorama InformationWith pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focusof the ...See all reports like this >>More Global Drug Delivery ReportsGlobal Drug Eluting Stents Market 2010-2014 by Infiniti Research LimitedTechNavio analysts forecast that the Global Drug Eluting Stents market will reach $5.7Billion in 2014. One of the key factors contributing to this markets ...World Diabetes Drug Market 2011-2021 by VisiongainWhere will revenue growth occur in the diabetes treatment market? Our new report
  • 5. shows you the potential that drug market offers from 2011 to 2021, ...Global Injectable Drug Delivery Market (2010 - 2015) by MarketsandMarketsKEY TAKE AWAYS To define and measure the Injectable drug delivery market and itsvarious sub-segments with respect to ...Drug Delivery: Surveying the Global Competitive Landscape by Espicom HealthcareIntelligenceThis report details some of the most exciting technology out there and the companieswho are developing ...Intranasal Drug Delivery by Global Industry AnalystsThis report analyzes the US market for Intranasal Drug Delivery in US$ Million by thefollowing Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, andVaccinations. Annual ...TABLE OF CONTENTSEXECUTIVE SUMMARY THE GLOBAL VACCINES INDUSTRY Scope and Methodology Overview Pediatric Preventative Vaccines The Market The Market Total Market Issues and TrendsCHAPTER TWO: INTRODUCTION TO VACCINES A Brief History: The Development of Vaccines The Immune Response Mechanism of Action Types of Vaccines Attenuated (Weakened) Live Viruses Killed (Inactivated) Viruses Toxoid Vaccines Genetically Engineered/Modified Vaccines  Subunit Vaccines  Conjugate Vaccines  DNA Vaccination Vaccine Approval Process
  • 6. CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES Introduction Childhood Immunization in the United States Childhood Immunization Rates Challenges to the Vaccine Delivery System The Effect of U.S. Healthcare Reform Recommended Childhood Immunization Schedule State Immunization Recommendations United Nations Initiatives Pediatric Vaccine Products BCG Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio  Diphtheria  Pertussis  Tetanus  Hepatitis B  Poliomyelitis  Enterotoxigenic Escherichia coli Haemophilus Influenzae Type B Hepatitis A Measles, Mumps and Rubella  Measles  Mumps  Rubella Meningococcal Disease Parainfluenza Virus Type 3 Pneumococcal Conjugate Rotavirus Respiratory Syncytial Virus Varicella Pediatric Vaccines in Development Cost of Vaccines in the United States The World Market for Pediatric Preventive Vaccines Total Market Size and Forecast Hepatitis Vaccine Market  Market Analysis  Leading Products and Competitors Haemophilus Influenzae Type B Vaccine Market  Market Analysis  Leading Products and Competitors Measles, Mumps and Rubella Vaccines   Market Analysis
  • 7. Combination Vaccines Market  Market Analysis  Leading Products and Competitors Pneumococcal Vaccine   Leading Products and Competitors Poliovirus Vaccine   Market Analysis  Leading Products and Competitors Varicella Vaccines  Market Analysis  Leading Products and Competitors Other Vaccines Market  Market Analysis  Leading Products and CompetitorsCHAPTER FOUR: ADULT PREVENTIVE VACCINES Introduction Adult Vaccine-Preventable Diseases: Facts and Figures Global Influenza Surveillance Program U.S. Surveillance Recommendations for Adult Immunizations WHO International Health Regulations Adult Vaccine Products Allergies Cervical Cancer Cholera Dengue Fever Diphtheria-Tetanus Hepatitis   Hepatitis A  Hepatitis B Influenza Japanese Encephalitis Malaria Pneumococcal Disease Rabies Shingles Typhoid Fever Yellow Fever Adult Vaccines in Development
  • 8. Total Market Size and Forecast Cervical Cancer Market Market Analysis Leading Products and Competitors Hepatitis Market Market Analysis Leading Products and Competitors Influenza Vaccine Market Market Analysis Leading Products and Competitors Market Analysis Leading Products and Competitors Travel, DT, and Miscellaneous Vaccine Market Market Analysis Leading Products and CompetitorsCHAPTER FIVE: VACCINES MARKET SUMMARY Trends Driving the Vaccines Market Market Size and Forecast Vaccine Sales by Region Vaccine Market Competitors Pediatric Vaccines Major Manufacturers’ Market Share Adult Vaccines Major Manufacturers’ Market ShareCHAPTER SIX: ISSUES AND TRENDS Vaccine Safety Refusal to Immunize Obesity Post-Licensure Surveillance  Vaccine Adverse Event Reporting System  The Vaccine Safety Datalink Project  Phase IV studies The Vaccine Injury Compensation Program  Countermeasures Injury Compensation Program World Health Organization Other Initiatives The Future of Vaccine Safety Vaccine Shortages Preventing Shortages in the Developed Countries  Financial incentives  Equitable pricing
  • 9.  Vaccine stockpiles Preventing Shortages in Developing Nations   Vaccine bonds Preventing Pandemics U.S. National Vaccine Plan Vaccines and Bioterrorism Overview Project Bioshield Act National Bio and Agro-Defense Facility Vaccine Treatment and Evaluation Units Anthrax Smallpox Tularemia Viral Hemorrhagic Fevers DTC Advertising of Vaccines DNA Vaccination Innovations in Vaccine Delivery Systems Edible Vaccines Mucosal Delivery Intranasal Delivery Vaccine Patches Vaccine Chips Innovations in Vaccine Production Tobacco Plants Insects Nanoparticle Systems CloningCHAPTER SEVEN: COMPANY PROFILES AlphaVax, Inc. History and Lines of Business Strategic Alliances Vaccine Products Financial Information Bavarian Nordic A/S History and Lines of Business Strategic Alliances
  • 10. Vaccine Products Financial InformationBaxter Healthcare History and Lines of Business Strategic Alliances Vaccine Products Financial InformationBharat Biotech History and Lines of Business Strategic Alliances Vaccine Products Financial InformationCelldex Therapeutics History and Lines of Business Strategic Alliances Vaccine Products Financial InformationCrucell /Johnson & Johnson History and Lines of Business Strategic Alliances Vaccine Products Financial InformationEmergent biosolutions History and Lines of Business Strategic Acquisition and Alliance Vaccine Products FinancialGlaxoSmithKline History and Lines of Business Strategic Alliances Vaccine Products Financial InformationMedimmune History and Lines of Business Strategic Alliances Vaccine Products Financial InformationMerck & Co. Inc History and Lines of Business Strategic Alliances Vaccine Products Financial InformationNabi Biopharmaceuticals History and Lines of Business Strategic Alliance Vaccine Products Financial InformationNovartis
  • 11. History and Lines of Business Strategic Alliances Vaccine Products Financial Information History and Lines of Business Strategic Alliances Vaccine Products Financial Information Sanofi Pasteur History and Lines of Business Strategic Alliances Vaccine Products Financial InformationCOMPANY DIRECTORY LIST OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Figure 1-1: World Market for Pediatric Vaccines 2005-2014 Revenues Figure 1-2: World Market for Adult Vaccines 2005-2014 RevenuesCHAPTER TWO: INTRODUCTION TO VACCINES Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2010 Figure 2-1: Attenuated Virus Production Table 2-2: Vaccine-Preventable Diseases, June 2011 Table 2-3: VAERS Table of Reportable Events Following VaccinationCHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES Table 3-1: Global Immunization Rates by Vaccine Type (DPT3, BCG, HepB, Yellow Fever, Tetanus, Hib, MCV, Polio) 2009 Table 3-2: Immunization Profile of the United States: Population by Age Group, Number of Vaccine-Preventable Diseases Reported by Disease 1990 - 2009 Table 3-3: U.S. Recommended Immunization Schedule for Children Ages 0 Through 6 Years, 2011 Table 3-4: U.S. Recommended Immunization Schedule for Adolescents Ages 7 to 18 Years, 2011 Table 3-5: Selected Pediatric Vaccines in Development, June 2011 Table 3-6: World Market for Pediatric Vaccines, 2006-2015.. Figure 3-1: Market Share of Pediatric Vaccines by Type 2010 Figure 3-2: Market Share of Pediatric Vaccines, by Type 2015 Table 3-7: World Market for Pediatric Vaccines by Region (U.S., Rest of North America, South America, EU, Japan, India, China, Rest of World) 2006-2015 Revenues
  • 12. Table 3-8: World Pediatric Hepatitis Vaccine Market 2006-2015 Table 3-9: World Hib Vaccine Market, 2006-2015 Table 3-10: World MMR Vaccines Market 2006-2015 Table 3-11: World Combination Vaccines Market 2006-2015 Table 3-12: World Pediatric Pneumococcal Vaccine Market 2006-2015 Table 3-13: World Poliovirus Vaccine Market 2006-2015 Table 3-14: World Varicella Vaccine Market 2006-2015 Table 3-15: World Pediatric Other Vaccines Market 2006-2015CHAPTER FOUR: ADULT PREVENTIVE VACCINES Table 4-1: Universal Adult Immunization Schedule 2011 Table 4-2: Adult Immunization Schedule for Populations with Special Medical Conditions, 2011 Table 4-3: Initiatives to Require HPV Vaccination by U.S. State, 2011 Table 4-4: WHO Pandemic Classification Schedule Table 4-5: Selected Adult Preventive Vaccines in Development, 2011 Table 4-6: World Market for Adult Preventive Vaccines, 2006-2015 Figure 4-1: Market Share of Adult Vaccines, by Type, 2010 Figure 4-2: Market Share of Adult Vaccines, by Type, 2015 Table 4-7: World Market for Adult Vaccines by Region (U.S., Rest pf North Amer., South America, EU, Japan, India, China, Rest of World) 2006-2015 Table 4-8: World Cervical CancerVaccine Market 2006-2015 Table 4-9: World Hepatitis Vaccine Market 2006-2015 World Influenza Vaccine Market 2006-2015 Table 4-11: 2010 Estimated Population by Region (Africa, Asia, Europe, N. America, Oceania, South America) and Selected Age Group (in millions) Table 4-12: World Pneumococcal Vaccine Market 2006-2015 World Travel; Diphtheria-Tetanus; Miscellaneous Vaccines Market 2006-2015CHAPTER FIVE: VACCINES MARKET SUMMARY Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals 2006-2015 Figure 5-2: World Market for Vaccines by Type 2006-2015 Table 5-1: The World Vaccines Market by Vaccine Type 2006-2015 Figure 5-3: World Market for Vaccines Share by Type (Pediatric, Adult), 2006, 2010 and 2015 Table 5-2: The World Vaccines Market by Region (U.S, Rest of North Amer., South America, EU, Japan, India, China, ROW) 2006-2015 Revenues (in millions) Table 5-3: Major Manufacturers’ Shares of the World Vaccine Market, 2010 Figure 5-3: 2010 World Vaccines Market Share, by Leading Competitors Table 5-4: Major Manufacturer’s Shares of the World Pediatric Vaccine Market 2010 Figure 5-5: Market Share of Pediatric Vaccines Market, 2010 Table 5-5: Major Manufacturer’s Shares of the World Adult Vaccine Market 2010
  • 13. Figure 5-6: Market Share of Adult Vaccines Market 2010CHAPTER SIX: ISSUES AND TRENDS Table 7-1: Selected Companies/Laboratories Developing Biodefense VaccinesAvailable immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=6277155US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004